The laureate professor at the University of Melbourne detailed the design and promising results of the PACIFIC trial of bexicaserin, an agent in development for epileptic encephalopathies. [WATCH TIME: 4 minutes]
Ingrid Scheffer, AO, PhD, FRACP, FAHMS, FAA
Advertisement
Articles by Ingrid Scheffer, AO, PhD, FRACP, FAHMS, FAA
Advertisement
Latest Updated Articles
Overviewing Phase 1/2 PACIFIC Trial of Bexicaserin in Developmental Epileptic Encephalopathies: Ingrid Scheffer, AO, PhD, FRACP, FAHMS, FAAPublished: September 4th 2025 | Updated:
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
VMAT2 Inhibitor NBI-1065890 Heads to Phase 2 Study in Tardive Dyskinesia
2
Phase 3 EMBARK Data Released, CTE Associated with Dementia Risk, Pilavapadin Heads to Phase 3 Pain Studies
3
Taysha Doses First Patient in Pivotal Trial for Rett Syndrome Gene Therapy TSHA-102, Aligns With FDA on BLA Plans
4
AAN Publishes First-Ever Guideline for Functional Seizure Care Management
5